Annual European BioPharma obesity innovation forum

Building on the success of the inaugural BioPharma Obesity Innovation Forum (#Sachs_BOIF) in San Francisco, we are pleased to launch its European edition. The 1st Annual European BioPharma Obesity Innovation Forum (#Sachs_EBOIF) will take place at The Westin Leipzig, Germany, on the 11th - 12th of June 2025, with the Virtual Week scheduled for the 18th - 19th of June.

The current obesity pandemic is arguably the greatest challenge to 21st-century global health. The pharmaceutical market is estimated to exceed $100 billion by 2030, notwithstanding the pressure on payers. More positively, we are also learning more and more about the broad health benefits of GLP-1 medicines beyond even cardio-metabolic diseases.

The conference will provide insights into GLP-1 innovation, combinations, new foundational therapies, and precision medicine, while also addressing the challenge of manufacturing. Delegates will gain a comprehensive understanding of Europe’s market and its role in shaping global innovation.

Our comprehensive two-day programme includes:

• 10+ hours of high-level keynotes, panel discussions, and corporate & scientific presentations
• Insights into drug development, technology innovations, and investment trends
• On-demand session access from the 18th of June for virtual participants

We anticipate 200+ delegates attending and 15+ company presentations, including emerging companies featured in our Rising Stars – Seed Companies Session.​

In-Person Meetings – 11th - 12th of June
Virtual Meetings via Online Meeting System – 18th - 19th of June
Networking Reception – 11th of June
Farewell Reception – 12th of June
On-Demand Content – from 18th of June

Members of the Swiss Biotech Association benefit from a 15% discount on registration or showcase packages with Online Meeting System Access.